CAR-T has a geography problem

The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

After a slow start for expensive CAR-T therapies, drug devel...

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o